The therapy consists of autologous peripheral blood mononuclear cells (PBMCs), which include various APCs, pulsed ex vivo with a fusion protein of GM‐CSF and prostatic acid phosphatase, a tumor‐associated antigen. Here, CSF2 is linked to neoplasm.